Table 3.

Relative risk of loss to follow-up at 18 months post-ART initiation for early enrollers of DSD models

	Proportion of patients lost to follow-up at 18 months, % (95% CI) (n/N)
	Early enrollers	Established enrollers	Unadjusted risk ratio (95% CI)	Adjusted risk ratio* (95% CI)
All patients	3.0 (2.6 to 3.5) (192/6340)	4.5 (4.3 to 4.8) (1169/25 857)	0.67 (0.57 to 0.78)	0.59 (0.50 to 0.68)
Stratification: DSD model
Adherence groups	2.7 (1.0 to 6.7) (4/149)	3.1 (1.9 to 5.1) (16/508)	0.85 (0.25 to 2.29)	0.79 (0.23 to 2.12)
Community pick-up points	4.5 (3.1 to 6.3) (30/671)	3.3 (2.5 to 4.3) (48/1461)	1.36 (0.86 to 2.12)	1.30 (0.81 to 2.03)
Extended clinic hours	10.6 (5.7 to 18.9) (9/85)	8.2 (4.2 to 15.4) (8/97)	1.28 (0.51 to 3.27)	1.19 (0.43 to 3.34)
Fast-track	3.4 (2.4 to 4.7) (33/979)	3.6 (3.2 to 4.1) (227/6266)	0.93 (0.64 to 1.31)	0.74 (0.50 to 1.05)
Home ART delivery	1.4 (0.6 to 3.3) (5/355)	6.3 (4.9 to 8) (61/973)	0.22 (0.08 to 0.50)	0.18 (0.06 to 0.41)
Multimonth dispensing	2.7 (2.3 to 3.2) (111/4101)	4.9 (4.6 to 5.2) (809/16 552)	0.55 (0.45 to 0.67)	0.51 (0.41 to 0.61)
Stratification: ART dispensing duration
<2 months	4.1 (2.8 to 5.9) (26/636)	10.6 (9.1 to 12.2) (156/1476)	0.39 (0.25 to 0.57)	0.40 (0.26 to 0.59)
3 months	3.5 (2.8 to 4.4) (77/2197)	5.3 (4.8 to 5.9) (303/5688)	0.66 (0.51 to 0.84)	0.64 (0.49 to 0.81)
4–6 months	2.5 (2.1 to 3.1) (89/3507)	3.8 (3.5 to 4.1) (709/18 679)	0.67 (0.54 to 0.83)	0.67 (0.53 to 0.82)

*Model adjusted for age, sex, location, ART dispensing duration and DSD model type.

ART, antiretroviral therapy; DSD, differentiated service delivery.